ReviewKidney research and clinical practice2016
Diagnosis and treatment of patients with IgA nephropathy in Japan.
Review in Kidney research and clinical practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Review
- Seasonal variations in renal biopsy numbers and primary glomerular disease features based on the Japan renal biopsy registry.Scientific reports · 2023Article
- Glomerular expression and urinary excretion of fatty acid-binding protein 4 in IgA nephropathy.Journal of nephrology · 2023Article
- Computational Pipeline for Glomerular Segmentation and Association of the Quantified Regions with Prognosis of Kidney Function in IgA Nephropathy.Diagnostics (Basel, Switzerland) · 2022Article
- Efficacy and indications of tonsillectomy in patients with IgA nephropathy: a retrospective study.PeerJ · 2022Article
- Dysbiosis in the Salivary Microbiome Associated with IgA Nephropathy-A Japanese Cohort Study.Microbes and environments · 2021Article
- Complement activation is associated with crescent formation in IgA nephropathy.Virchows Archiv : an international journal of pathology · 2020Article
- Severity of foot process effacement is associated with proteinuria in patients with IgA nephropathy.Kidney research and clinical practice · 2020Article
- Age-adjusted global glomerulosclerosis predicts renal progression more accurately in patients with IgA nephropathy.Scientific reports · 2020Article
- Article
- Chronic kidney disease: a review of proteomic and metabolomic approaches to membranous glomerulonephritis, focal segmental glomerulosclerosis, and IgA nephropathy biomarkers.Proteome science · 2019Review
- Article
- The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition.Pediatric nephrology (Berlin, Germany) · 2018Article
- Kartagener syndrome complicated by immunoglobulin A nephropathy.International medical case reports journal · 2018Article
- Urinary Exosome-Derived microRNAs Reflecting the Changes in Renal Function in Cats.Frontiers in veterinary science · 2018Article
- Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.PloS one · 2018Article
- Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.BMC pharmacology & toxicology · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a worldwide public health problem that affects millions of people from all racial and ethnic groups. Although CKD is not one specific disease, it is a comprehensive syndrome that includes IgA nephropathy. As reported by the Japanese Society of Nephrology, 13.0 million people have CKD. In Japan, major causes of end-stage kidney disease are type 2 diabetic nephropathy, chronic glomerulonephritis, especially IgA nephropathy, hypertensive nephrosclerosis, and polycystic kidney disease. IgA nephropathy is characterized by polymeric IgA1 with aberrant galactosylation (galactose-deficient IgA1) increased in the blood and deposited in the glomerular mesangial areas, as well as partially in the capillary walls. The tonsils are important as one of the responsible regions in this disease. The clarification of the mechanism of galactose-deficient IgA1 production will pave the way for the development of novel therapies. The results of future research are eagerly awaited. At present, the most important therapeutic goals in patients with IgA nephropathy are the control of hypertension, the decrease of urinary protein excretion, and the inhibition of progression to end-stage kidney disease. Several investigators have reported that renin-angiotensin-aldosterone system inhibitors reduce levels of urinary protein excretion and preserve renal function in patients with IgA nephropathy. In Japan, tonsillectomy and steroid pulse therapy are more effective for patients with IgA nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.